Literature DB >> 12881398

Measuring progress against cancer in Europe: has the 15% decline targeted for 2000 come about?

P Boyle1, A d'Onofrio, P Maisonneuve, G Severi, C Robertson, M Tubiana, U Veronesi.   

Abstract

BACKGROUND: Against a background of increasing cancer rates in the mid-1980s, Europe Against Cancer launched an ambitious programme aiming to reduce cancer mortality by 15% by the year 2000. A programme of activities and research, focussing on three major themes [prevention (particularly tobacco control), screening, and education and training], was developed together with the European Code Against Cancer.
METHODS: To evaluate the outcome of the programme, all cancer mortality data were abstracted for each member state of the European Union (EU) until the most recent year available. For each gender group in each member state, age-specific rates were estimated for 2000. For each country-gender grouping, the standardized mortality rate (SMR) and expected numbers of deaths in 2000 were calculated based on the age-specific rates for 1985 and the population estimates for 2000. The ratio of the SMR in 2000 to that of 1985, was used as the measure to compare mortality rates.
RESULTS: In 1985, there were 850 194 cancer deaths in the EU. Based solely on demographic considerations, this number was expected to rise to 1 033 083 in the year 2000. Between 1985 and 2000, the number of cancer deaths increased in both men (+12%) and women (+9%). The target of a 15% reduction in the expected numbers of cancer deaths in the EU was not met, although the 10% reduction in number of deaths expected in men and 8% in women, along with a 11% reduction in risk of cancer death in men and a 10% reduction in women, was noteworthy. Only Austria and Finland achieved the 15% reductions in deaths in both men and women. The UK and Luxembourg (where the small population and annual number of deaths make interpretation difficult) came close to meeting these targets, as did Italy. Portugal and Greece had the poorest performance, with increases in each gender group.
CONCLUSIONS: Cancer deaths in the EU were expected to rise from 850 194 in 1985 to 1 033 083 in 2000. It is estimated that there will be 940 510 cancer deaths that year, due to the decline in risk observed since 1985. The Europe Against Cancer programme appears to have been associated with the avoidance of 92 573 cancer deaths in the year 2000. With few exceptions, most countries are experiencing declining trends in cancer death rates, which seem set to continue, at least in the near future. Renewed tobacco control efforts are clearly needed for women, and there is a strong case for the introduction of organized breast and cervix screening programmes in all member states. Continuing to emphasize prevention within cancer control will help to promote the continuing decline in death rates in the future.

Entities:  

Mesh:

Year:  2003        PMID: 12881398     DOI: 10.1093/annonc/mdg353

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  16 in total

1.  Evaluation of time, attendance of medical staff, and resources during radiotherapy for breast cancer patients. The DEGRO-QUIRO trial.

Authors:  E Blank; N Willich; R Fietkau; W Popp; J Schaller-Steiner; H Sack; F Wenz
Journal:  Strahlenther Onkol       Date:  2012-01-14       Impact factor: 3.621

2.  Heterogeneity of prognostic profiles in non-small cell lung cancer: too many variables but a few relevant.

Authors:  Agustín Gomez de la Cámara; Angel López-Encuentra; Paloma Ferrando
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

3.  Trends of mortality in Greece 1980-2007: a focus on avoidable mortality.

Authors:  M Ollandezos; Th Constantinidis; K Athanasakis; Ch Lionis; J Kyriopoulos
Journal:  Hippokratia       Date:  2011-10       Impact factor: 0.471

4.  Estrogen induced breast cancer is the result in the disruption of the asymmetric cell division of the stem cell.

Authors:  Jose Russo; Kara Snider; Julia S Pereira; Irma H Russo
Journal:  Horm Mol Biol Clin Investig       Date:  2010-01-01

5.  Evaluation of time, attendance of medical staff, and resources during radiotherapy for head and neck cancer patients: the DEGRO-QUIRO trial.

Authors:  Wilfried Budach; Edwin Bölke; Rainer Fietkau; Andre Buchali; Thomas G Wendt; Wolfgang Popp; Christiane Matuschek; Horst Sack
Journal:  Strahlenther Onkol       Date:  2011-07-22       Impact factor: 3.621

6.  New advances in breast cancer metastasis.

Authors:  Jose Russo; Hye-Jung Han; Yoshinori Kohwi; Terumi Kohwi-Shigematsu
Journal:  Womens Health (Lond)       Date:  2008-11

7.  Colorectal cancer screening in Europe.

Authors:  Miroslav Zavoral; Stepan Suchanek; Filip Zavada; Ladislav Dusek; Jan Muzik; Bohumil Seifert; Premysl Fric
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

8.  Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity.

Authors:  Linda Hughes; Catherine Malone; Saranya Chumsri; Angelika M Burger; Susan McDonnell
Journal:  Clin Exp Metastasis       Date:  2008-04-02       Impact factor: 5.150

9.  Implementation of a comprehensive cancer plan. A health planning experience.

Authors:  José Expósito Hernández; Carmen Domínguez Nogueira; Carmen Escalera de Andrés
Journal:  Clin Transl Oncol       Date:  2008-04       Impact factor: 3.405

10.  Trends in socioeconomic inequalities in cancer mortality in Barcelona: 1992-2003.

Authors:  Rosa Puigpinós; Carme Borrell; José Leopoldo Ferreira Antunes; Enric Azlor; M Isabel Pasarín; Gemma Serral; Mariona Pons-Vigués; Maica Rodríguez-Sanz; Esteve Fernández
Journal:  BMC Public Health       Date:  2009-01-23       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.